Ascendi Vision News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ascendi vision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ascendi Vision Today - Breaking & Trending Today

Ascendis Pharma Introduces Vision 2030

Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference. “With unwavering focus on our values of P ....

United States , Jan Mikkelsen , Ascendis Pharma , Melinda Baker , Tim Lee , Therapeutics Asia Pte Ltd , Be The Leading Endocrinology Rare Disease Company , Teijin Limited For Transcon , Exchange Commission , Patti Bank , Endocrinology Rare Disease , Chief Executive , Biologics License Application , Prescription Drug User Fee Act , Achondroplasia Child Experience , Clinical Trial Application , New Drug Application , Investigational New Drug , Endocrinology Rare , Teijin Limited , Japan Trial , International Markets , Specialised Therapeutics Asia Pte Ltd , Vector Pharma , Ophthalmology Newco , Outlook Based ,

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United States , New Jersey , Palo Alto , Redwood City , Baden Wüberg , South Korea , Ascendis Pharma , Jan Mikkelsen , Exchange Commission , Ascendis Pharma Group , European Commission , Drug Administration , Devices Agency , Ascendis Pharma Hp Patient Experience Research , Clinical Trial Notification , Medical Devices Agency , Japan Trial , North America , Greater China , Orphan Drug Designation , Orphan Designation , Ascendi Vision , Ascendi Annual Report , Bone Miner , Bone Miner Res , Clin Endocrinol Metab ,

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
– Advances Vision 3×3 to extend global clinical and commercial reach –
COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity investment of $12.5 million in VISEN Pharmaceuticals (VISEN) as part of VISEN’s $150 million Series B financing.
“Our relationship with VISEN is a key element of our Vision 3×3 strategy to extend the global reach of our TransCon endocrinology rare disease product candidates and improve patients’ lives around the world,” said Jan Mikkelsen, President and CEO at Ascendis Pharma. “Since VISEN’s inception in 2018, the company has made significant progress on its clinical activities in Greater China, which we believe will enable us to get our products to pat ....

Hong Kong , New Jersey , United States , Palo Alto , Redwood City , Baden Wuberg , Ascendis Pharma , Jan Mikkelsen , Michael Wolff Jensen , Exchange Commission , Technology Platform , Advances Vision , Greater China , Senior Vice President , Chief Legal Officer , Vivo Capital , Sofinnova Ventures , Ascendi Vision , Annual Report , ஹாங் காங் , புதியது ஜெர்சி , ஒன்றுபட்டது மாநிலங்களில் , பாலோ ஆல்டோ , ரெட்வுட் நகரம் , ஜான் மைக்கேல்சன் , மைக்கேல் ஓநாய் ஜென்சன் ,